ARCA biopharma approves 1-for-12 reverse stock split
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 23 2024
0mins
Should l Buy ?
Source: SeekingAlpha
Reverse Stock Split Announcement: ARCA biopharma has approved a 1-for-12 reverse stock split, reducing its shares from approximately 14.5 million to about 1.2 million, effective September 3, 2024.
Company Name and Symbol Change: Following the merger with Oruka, ARCA will change its name to Oruka Therapeutics and its trading symbol to "ORKA" on the Nasdaq Global Market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
